GlaxoSmithKline’s kidney cancer drug Votrient has been forecast as a future leader in a marketplace currently dominated by Pfizer. Analysts …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

